Stocktoria
NOVAVAX INC NVAX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1973-05-16
NOVAVAX INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $682.2M | $983.7M | $2.0B | $1.1B |
| R&D expense | $342.3M | $391.2M | $737.5M | $1.2B | $2.5B |
| SG&A expense | $157.5M | $337.2M | $468.9M | $488.7M | — |
| Operating income | $452.8M | -$248.9M | -$566.5M | -$644.7M | -$1.7B |
| Interest expense | — | — | $14.4M | $19.9M | $21.1M |
| Income tax | $1.9M | $10.9M | $2.0M | $4.3M | $29.2M |
| Net income | $440.3M | -$187.5M | -$545.1M | -$657.9M | -$1.7B |
| EPS (diluted) | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 |
| Operating cash flow | -$244.6M | -$87.3M | -$714.0M | -$415.9M | $322.9M |
| Cash & equivalents | $240.6M | $530.2M | $568.5M | $1.3B | $1.5B |
| Inventory | $11.5M | $8.7M | $41.7M | $36.7M | $8.9M |
| Total assets | $1.2B | $1.6B | $1.8B | $2.3B | $2.6B |
| Total liabilities | $1.3B | $2.2B | $2.5B | $2.9B | $2.9B |
| Shareholders' equity | -$127.8M | -$623.8M | -$716.9M | -$634.1M | -$351.7M |
Source: SEC EDGAR filings · CIK 0001000694 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.